盛德鑫泰(300881) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥263,886,323.13, representing a 27.84% increase compared to ¥206,418,371.20 in the same period last year[3] - Net profit attributable to shareholders was ¥13,087,220.86, an increase of 11.81% from ¥11,704,439.68 year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥12,958,068.56, up 44.36% from ¥8,976,318.53 in the previous year[3] - The total operating revenue for Q1 2022 was CNY 263,886,323.13, an increase of 27.8% compared to CNY 206,418,371.20 in Q1 2021[17] - The net profit for Q1 2022 reached CNY 13,087,220.86, representing a 12.0% increase from CNY 11,704,439.68 in Q1 2021[18] - The company's basic and diluted earnings per share for Q1 2022 were both CNY 0.13, compared to CNY 0.12 in Q1 2021[18] Assets and Liabilities - The company's total assets increased by 2.95% to ¥1,547,734,581.68 from ¥1,503,441,128.71 at the end of the previous year[3] - The total assets as of the end of Q1 2022 were CNY 1,547,734,581.68, compared to CNY 1,503,441,128.71 at the end of Q1 2021[16] - The total liabilities for Q1 2022 were CNY 757,612,935.38, an increase from CNY 727,347,617.22 in Q1 2021[16] - The company's total equity as of Q1 2022 was CNY 790,121,646.30, up from CNY 776,093,511.49 in the same period last year[16] Cash Flow - The net cash flow from operating activities was negative at -¥172,983,076.32, a significant decline of 491.77% compared to -¥29,231,267.87 in the same period last year[3] - The net cash flow from operating activities was -172,983,076.32, a significant decrease compared to -29,231,267.87 in the previous period, indicating a worsening cash flow situation[20] - Total cash inflow from investment activities was 151,732,333.34, while cash outflow was 166,765,598.40, resulting in a net cash flow of -15,033,265.06, an improvement from -55,009,342.61 previously[21] - Cash inflow from financing activities amounted to 199,536,723.21, a substantial increase from 52,086,555.56 in the prior period, reflecting enhanced financing efforts[21] - The net cash flow from financing activities was 164,904,847.50, a significant increase compared to 459,795.91 in the previous period, indicating improved financial stability[21] - The total cash and cash equivalents at the end of the period were 56,227,117.31, down from 79,338,611.19, showing a decrease in liquidity[21] Operational Costs - The total operating costs for Q1 2022 were CNY 248,475,654.83, up 25.6% from CNY 197,739,395.47 in the same period last year[17] - Cash paid for purchasing goods and services was 257,304,841.27, an increase from 208,714,116.02, indicating rising operational costs[20] - Cash paid to employees was 21,355,440.80, up from 19,980,472.53, suggesting increased labor costs[20] Investments and Shareholders - The company has invested in several biotech firms, including a 0.3476% stake in Jiangsu Quanxin Biomedical Co., Ltd.[12] - Major shareholders include Zhou Wenqing with 43.50% and Zong Huanqin with 20.25% of shares[11] - The company has established employee stock ownership platforms, holding 7.85% and 1.90% of shares respectively[11] - The company’s major shareholders have familial relationships, with Zhou Wenqing and Zong Huanqin being spouses[11] Research and Development - Research and development expenses rose by 44.67% to ¥10,586,336.91 from ¥7,317,808.72 year-over-year, indicating increased investment in R&D[8] - Research and development expenses for Q1 2022 amounted to CNY 10,586,336.91, which is a 44.5% increase from CNY 7,317,808.72 in the previous year[17] Accounts Receivable and Payable - The company reported a 365.83% increase in accounts receivable financing, reaching ¥63,778,372.19 compared to ¥13,691,289.36 at the end of the previous year[8] - The company experienced a 40.25% increase in accounts payable, amounting to ¥71,322,234.10, attributed to higher raw material purchases in Q1[8] - Accounts receivable increased to 306,301,625.73 CNY from 297,812,715.90 CNY, reflecting a growth of about 2.6%[14] - Inventory has risen to 241,263,789.28 CNY from 210,444,254.16 CNY, indicating an increase of approximately 14.7%[14] Audit and Compliance - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[22]